NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $3.16 to $3.96
• 50-Day Range: $0.58 to $4.22
• 52-Week Range: $0.44 to $4.44
• Volume: 9.49 million shs
• Average Volume: 2.56 million shs
• Market Capitalization: $21.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.85
• Consensus Rating: Buy

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

NovaBay Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat, and ranked 900th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

NovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Downside Risk

NovaBay Pharmaceuticals has a consensus price target of $0.85, representing about 77.2% downside from its current price of $3.73.

Amount of Analyst Coverage

NovaBay Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($3.26) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovaBay Pharmaceuticals has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NBY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovaBay Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NovaBay Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NBY.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

11 people have searched for NBY on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

MarketBeat Follows

4 people have added NovaBay Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed this year?

NovaBay Pharmaceuticals' stock was trading at $0.6010 at the beginning of the year. Since then, NBY stock has increased by 520.6% and is now trading at $3.73.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.32. The firm had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.50 million. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 7,293.78% and a negative net margin of 102.72%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals's stock reverse split before market open on Friday, May 31st 2024.The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' top institutional investors include C2C Wealth Management LLC (1.69%).
View institutional ownership trends.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 9/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NBY
• CIK: 1389545
• Web: novabay.com
• Phone: 510-899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NovaBay Pharmaceuticals: $0.85
• High Price Target: $0.85
• Low Price Target: $0.85
• Potential Upside/Downside: -77.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($53.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.64 million
• Net Margins: -102.72%
• Pretax Margin: -99.12%
• Return on Equity: -7,293.78%
• Return on Assets: -158.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $9.78 million
• Price / Sales: 2.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 5,824,000
• Free Float: 4,881,000
• Market Cap: $21.72 million
• Optionable: Not Optionable
• Beta: 0.60